Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe.
The agreement focuses on expanding the accessibility of this cancer treatment to individuals in up to 32 nations.
LEO Pharma will manage the distribution, promotion and sales of the antibody across European Union member states, Switzerland, the UK and the European Economic Area.
TopAlliance Biosciences Europe will retain its role as the marketing authorisation holder, overseeing product development, manufacturing and other key responsibilities.
The collaboration includes financial arrangements such as an upfront payment, milestone payments for potential future indications and a revenue share agreement based on net sales.
LEO Pharma thrombosis business unit executive vice-president Jean Monin stated: “We are excited to partner with Junshi Biosciences, supplementing LEO Pharma’s Thrombosis business, which already serves patients with cancer-associated thrombosis.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
“The distribution and marketing partnership for LOQTORZI brings an important new treatment option to areas of high unmet medical need and focuses on a speciality hospital product that complements our existing heparin-based anti-coagulation treatments for cancer-associated thrombosis and other speciality patients. Leveraging our commercial platform, LOQTORZI will create valuable synergies and drive continued growth.”
Developed by Junshi Biosciences, toripalimab targets programmed cell death protein 1 (PD-1), and is used in treating various tumours.
Its mechanism involves blocking PD-1 interactions with PD-L1 and PD-L2, enhancing the immune system’s ability to eliminate malignant cells. It has gained marketing approval in more than 35 countries and regions globally.
In 2024, the European Commission and the UK Medicines and Healthcare Products Regulatory Agency approved the therapy for two indications, making it the first treatment for nasopharyngeal carcinoma in Europe and a first-line treatment for advanced oesophageal squamous cell carcinoma.
Junshi has conducted more than 40 company-sponsored clinical studies of the therapy.
In May 2023, Shanghai Junshi Biosciences partnered with Dr. Reddy’s Laboratories to develop and commercialise toripalimab in 21 countries.
